Article
ALK rearrangements in EBUS-derived transbronchial needle aspiration cytology in lung cancer.
Cytopathology : official journal of the British Society for Clinical Cytology - 1 Dec 2013
Neat M J, Foot N J, Hicks A, Breen R, Wilkins B, McLean E, Santis G
Abstract excerpt
OBJECTIVES: Patients with non-small cell lung cancer (NSCLC) positive for anaplastic lymphoma kinase (ALK) gene rearrangements may be treated successfully with the ALK inhibitor crizotinib. ALK copy-number abnormalities have also been described. In this study, we evaluated the suitability of fluorescence in situ hybridization (FISH) and immunohistochemistry (IHC) to determine ALK status in endobronchial...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
